This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeuroMetrix CEO Interviewed On CEONEWS.Tv

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of neurological complications of diabetes announced that Chief Executive Officer Shai N. Gozani, M.D., Ph.D. has been interviewed on CEONEWS.Tv, a financial news network. The interview is available at: http://www.ceonews.tv/nuro/

In the interview, Dr. Gozani discussed his vision for NeuroMetrix and the company’s early success with NC-stat ® DPNCheck™, a fast, accurate, and quantitative test for diabetic peripheral neuropathy (DPN). DPN is a nerve disease that affects over 50% of patients with diabetes and can lead to foot ulcers and amputation. Dr. Gozani reviewed the market opportunity and most important market segments. He also outlined the company’s R&D pipeline and important milestones for 2012. The company recently completed an $8.5M public offering to fund its commercial and product development efforts. NeuroMetrix was founded in 1996 and has been publicly traded on Nasdaq since 2004, he noted.

NeuroMetrix was also recently featured in the Conservative Speculator which can be viewed at http://wallstreetcorner.com/cs/NURO.pdf

About NeuroMetrix

NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit http://www.neurometrix.com.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SYM TRADE IT LAST %CHG
AAPL $93.79 0.10%
FB $101.98 0.07%
GOOG $682.32 -0.12%
TSLA $150.99 0.35%
YHOO $27.04 1.00%

Markets

Chart of I:DJI
DOW 15,973.56 +313.38 2.00%
S&P 500 1,863.10 +34.02 1.86%
NASDAQ 4,335.5170 +68.68 1.61%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs